NYSE:BMY
Bristol Myers Squibb (BMY)
Financials 
Technical Analysis 
May 26, 2026, 12:00 amThis summary was created by AI, based on 9 opinions in the last 12 months.
Bristol Myers Squibb (BMY) has generated mixed reviews from experts. While some highlight its attractive dividend, strong drug pipeline, and recent financial performance—such as beating EPS and sales estimates along with raising future revenue guidance—others express concerns regarding the disappointing performance of certain drugs, particularly Cobenfy. The company has seen growth in its newer drug sales but struggles with its legacy portfolio. There are indications that the stock is at a low price point and has potential for recovery if the growth portfolio continues to outperform, making it a point of interest for investors, albeit with caution due to risks associated with its drug pipeline.
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
EPS of $1.63 beat estimates of $1.52 and sales of $12.2B beat estimates of $11.8B. Sales grew 3%, and management raised its 2025 revenue guidance to a range of $47.5B to $48.0B. Its growth portfolio sales of newer/higher-growth drugs were up 18% year-over-year, while its legacy portfolio sales were down 12%. These were decent results, and the price action looks decent, we think there is possibility that the name can rebound eventually if its growth portfolio continues to outpace its legacy portfolio.
Unlock Premium - Try 5i Free
They have huge oncology franchise, but face a huge patent cliff. But they have a some promising drugs. He owns this partly for the 5.6% dividend. He took shares off the table when the stock spiked earlier this year, but at current levels, he's watching the price go lower before buying again.
It's turned around in the last 6 months under the new CEO, rallying 40%. In the face of expiring drug patents, they launched a revolutionary schizophrenia drug. He also likes the rest of their pipeline to treat cardiovascular disease and oncology. He bought shares late last year.
Stock has been hot since the summer when the new CEO took over, then they got approval for their schizophrenia drugs. (Abbvie's drug failed last month.) But BMY has fallen 9% in the past 4 weeks--maybe because of concerns over the group, not the stock. Trades at only 7.9x PE 2025, and pays a 4.4% dividend which just increased last week. The stock is dirt cheap.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Bristol Myers Squibb (BMY) Frequently Asked Questions
What is Bristol Myers Squibb stock symbol?
Bristol Myers Squibb is a American stock, trading under the symbol BMY (previously BMY-N on Stockchase) on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY
Is Bristol Myers Squibb a buy or a sell?
In the last year, 9 stock analysts published opinions about BMY (previously BMY-N on Stockchase). 3 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY on WEAKNESS. Read the latest stock experts' ratings for Bristol Myers Squibb.
Is Bristol Myers Squibb a good investment or a top pick?
Bristol Myers Squibb was recommended as a Top Pick by Jim Cramer - Mad Money on 2024-12-16. Read the latest stock experts ratings for Bristol Myers Squibb.
Why is Bristol Myers Squibb stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Bristol Myers Squibb worth watching?
9 stock analysts on Stockchase covered Bristol Myers Squibb in the last year. It is a trending stock that is worth watching.
What is Bristol Myers Squibb stock price?
On 2026-05-26, Bristol Myers Squibb (BMY) stock closed at a price of $58.03.
Pays a really nice dividend. Really nice drug pipeline. Inexpensive. Reasonably wide moat.